Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lifecore Biomedical, Inc. \De\

NASDAQ: LFCR · Life Sciences · 6 alerts · CIK 1005286

Share price
$6.41Close, Nov 16
Market cap
$243M
Shares outstanding
37.91MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lifecore Biomedical, Inc. \De\ filings on SEC EDGAR ↗

7:15 AM ET 10-Q
Financial Results

Lifecore Biomedical, Inc. \De\ Q3 2026 Results: Net Loss of $40.1M, Loss Widens

Lifecore Biomedical reported a significant net loss of $61.2 million for the nine months ended September 30, 2026, compared to a $20.9 million loss in the prior year, primarily driven by a $35.6 million non-cash change in the fair value of a related party debt derivative. Total revenues decreased to $82.7 million from $105.7 million year-over-year, and the company recently entered into a merger agreement with affiliates of Webster Equity Partners.

Key figure
Net loss $40.1M
7:14 AM ET 8-K
Financial Results

Lifecore Biomedical, Inc. \De\ Financial Results

Lifecore Biomedical reported Q3 2026 financial results, showing a revenue decrease of 18.6% to $25.3 million compared to the prior year. The company reported a net loss of $40.1 million, or $1.08 per diluted share, while highlighting several new business wins in its CDMO pipeline including technology transfer projects and development-phase programs.

Term
Q3 2026

“During the third quarter, Lifecore secured two new technology transfer projects. One will support process performance qualification (PPQ) batches for a biotech company’s new drug application (NDA) for a new chemical entity, and the other will support a currently marketed product for a large pharmaceutical company. We believe these programs will add to Lifecore’s high-value pipeline, and we expect each to contribute to the company’s long-term revenue growth objectives, beginning in 2027”

Paul Josephs, president and chief executive officer of Lifecore

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.